Todd Krueger
CEO & President, AOB Pharma
Todd Krueger is the Chief Executive Officer, President and a Director of AOB Pharma (AOB). He is primarily responsible for the overall management, corporate development and strategic planning of AOB and has been with the company since 2015. Mr. Krueger graduated from Northwestern University with a Bachelor of Economics degree with Highest Distinction, and earned his Master of Business Administration degree from the Kellogg School of Management, Northwestern University.
Prior to joining AOB, Mr. Krueger had over 20 years of experience in healthcare strategy, business development, operations and finance. He started his career as a consultant for Bain and Company, a management consulting firm, from 1990 to 1993, responsible for providing strategic analysis and solution implementation to Fortune 500 clients. In 1999, Mr. Krueger co-founded Fluidigm Corporation, which is principally engaged in the design, manufacture and sale of biological research equipment and is currently listed on NASDAQ (stock symbol FLDM), where he served as its chief financial officer and the vice-president of business development from 1999 to 2002, responsible for strategy development, finance, business development, and operations. From 2006 to 2013 he held various senior business development and strategy roles at Applied Biosystems Inc. and later Life Technologies Corporation (which was formed as a result of the merger between Applied Biosystems Inc. and Invitrogen Corporation in 2008), where his last role was head of business development for molecular medicine. From 2013 to 2014, he was Chief Financial Officer of Claritas Genomics, Inc., a genetic diagnostics laboratory based in the United States, and from 2014 to 2015, he was the director of strategy and operations for the Broad Institute, a biomedical and genomic research center based in the United States. He was responsible for overseeing the commercialization of the genetics platform.
Mr. Krueger is also on the Board of Directors at Neofluidics, a manufacture of instrumentation for lipid nanoparticles, Tenza, a spinout of George Church’s lab focused on delivering drugs to mucosal surfaces using proprietary bacterial secretion technology, and General Automation Laboratory Technologies, Inc. (GALT), a microbiome tools company based in the United States.